Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 18.34% is 59% above its 5-year average of 11.55%, near the high end of its 5-year range (4.05%–18.34%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.12% above its 12-month average of 16.50%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): 3.83%.
RETURN ON ASSETS (ROA)
18.34%
RETURN ON ASSETS (ROA) AVG TTM
16.50%
RETURN ON ASSETS (ROA) AVG 3Y
12.68%
RETURN ON ASSETS (ROA) AVG 5Y
11.55%
RETURN ON ASSETS (ROA) AVG 10Y
13.80%
RETURN ON ASSETS (ROA) AVG 15Y
8.63%
RETURN ON ASSETS (ROA) AVG 20Y
5.18%
CURRENT VS TTM AVG
+11.12%
CURRENT VS 3Y AVG
+44.67%
CURRENT VS 5Y AVG
+58.72%
CURRENT VS 10Y AVG
+32.88%
CURRENT VS 15Y AVG
+112.59%
CURRENT VS 20Y AVG
+253.76%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+156.89%
vs the sector median at left
Pro-Dex, Inc.
Market Cap
$207.27M
Return on Assets (ROA)
18.34%
TTM Avg
16.50%
3Y Avg
12.68%
5Y Avg
11.55%
Market Cap
$208.31M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.80M
Return on Assets (ROA)
-41.15%
TTM Avg
-52.11%
3Y Avg
-46.68%
5Y Avg
-45.82%
Market Cap
$209.91M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$210.41M
Return on Assets (ROA)
-55.47%
TTM Avg
-12.81%
3Y Avg
-16.15%
5Y Avg
-23.71%
Market Cap
$210.98M
Return on Assets (ROA)
-79.86%
TTM Avg
-75.29%
3Y Avg
-50.35%
5Y Avg
-41.02%
Market Cap
$200.96M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$214.24M
Return on Assets (ROA)
15.00%
TTM Avg
14.43%
3Y Avg
-2.68%
5Y Avg
-18.26%
Market Cap
$214.46M
Return on Assets (ROA)
-34.38%
TTM Avg
-28.15%
3Y Avg
-48.34%
5Y Avg
-48.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pro-Dex, Inc. (PDEX) | $207.27M | 18.34% | 16.50% | 12.68% | 11.55% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -41.15% | -52.11% | -46.68% | -45.82% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 25.43% | 5.08% | -10.27% | -14.74% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -55.47% | -12.81% | -16.15% | -23.71% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -79.86% | -75.29% | -50.35% | -41.02% |
| Alector, Inc. (ALEC)vs › | $200.96M | -58.10% | -37.08% | -28.02% | -25.91% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 15.00% | 14.43% | -2.68% | -18.26% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -34.38% | -28.15% | -48.34% | -48.34% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.17% | 16.86% | 29.92% | 34.25% |
ROA
18.3%
ROE
28.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | 18.34% |
| 2025-06-30 | 14.67% |
| 2024-06-30 | 4.05% |
| 2023-06-30 | 13.65% |
| 2022-06-30 | 9.31% |
| 2021-06-30 | 9.31% |
| 2020-06-30 | 19.64% |
| 2019-06-30 | 16.25% |
| 2018-06-30 | 8.14% |
| 2017-06-30 | 31.09% |
| 2016-06-30 | 7.37% |
| 2015-06-30 | -2.92% |
| 2014-06-30 | -4.17% |
| 2013-06-30 | -16.84% |
| 2012-06-30 | -6.83% |
| 2011-06-30 | 16.97% |
| 2010-06-30 | -20.79% |
| 2009-06-30 | -17.28% |
| 2008-06-30 | 1.46% |
| 2007-06-30 | 2.79% |
| 2006-06-30 | 4.66% |
| 2005-06-30 | 14.50% |
| 2004-06-30 | 10.38% |
| 2003-06-30 | 1.46% |
| 2002-06-30 | -15.71% |
| 2001-06-30 | 24.24% |
| 2000-06-30 | 9.38% |
| 1999-06-30 | -50.48% |
| 1998-06-30 | 1.55% |
| 1997-06-30 | -6.61% |
